Clinical benefit and quality of life during low-dose sorafenib maintenance therapy in radioiodine refractory differentiated thyroid cancer patients: A historical cohort study

Publish Year: 1402
نوع سند: مقاله ژورنالی
زبان: English
View: 196

This Paper With 7 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IRJNM-31-1_006

تاریخ نمایه سازی: 4 بهمن 1401

Abstract:

Introduction: Effective management of radioiodine (RAI)-refractory differentiated thyroid cancer is a challenge due to limited treatment options. Multikinase inhibitor therapy including sorafenib has been an optional treatment in recent years. This study aims to compare the clinical benefit rate, progression free survival, and quality of life between patients who received limited dose of sorafenib (۲۰۰-۴۰۰ mg per day) as opposed to the control group.Methods: Twenty-two patients who received sorafenib and twenty-three cases in the control group were studied for two years. Baseline variables were comparable between two subgroups. The results of diagnostic imaging methods were also taken into consideration. Quality of life was measured using the EORTC (European Organization for Research and Treatment of Cancer) quality of life questionnaire.Results: Based on the RECIST (Response Evaluation Criteria in Solid Tumors) criteria, clinical benefit rate was ۷۷.۳% and ۴۷.۸% in sorafenib and control subgroups respectively (p value=۰.۰۴۲). The median of progression free survival for the sorafenib subgroup was ۲۴ months and in the control subgroup was ۲۲ months (p value=۰.۰۲۰). In a comparison between two groups regarding their quality of life, all subscales were statistically insignificant between the two groups except for the symptom subscale (p value=۰.۰۰۱).Conclusion: Low-dose sorafenib maintenance therapy is an effective treatment option in RAI- refractory differentiated thyroid cancer with the main effect of stabilizing the disease. Except for unpleasant but tolerable adverse effects, this treatment has no significant negative influence on the quality of life as far as the physical, role, cognitive, emotional, financial and social functions are concerned.Keywords: Multikinase inhibitors; Sorafenib; Differentiated thyroid cancer; Radioiodine treatment; Progression free survival

Authors

Babak Fallahi

Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Khatere Moharrami

Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Davood Beiki

Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Armaghan Fard-Esfahani

Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Kamran Alimoghaddam

Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

Mohammad Eftekhari

Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Karapanou O, Simeakis G, Vlassopoulou B, Alevizaki M, Saltiki K. ...
  • Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, ...
  • Jayarangaiah A, Sidhu G, Brown J, Barrett-Campbell O, Bahtiyar G, ...
  • Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, ...
  • Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, ...
  • Keefe SM, Troxel AB, Rhee S, Puttaswamy K, O'Dwyer PJ, ...
  • Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, ...
  • Jean GW, Mani RM, Jaffry A, Khan SA. Toxic effects ...
  • Shen CT, Qiu ZL, Luo QY. Sorafenib in the treatment ...
  • Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, ...
  • Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, ...
  • Santos FS, Santos RJ, Leite V. Sorafenib and sunitinib for ...
  • Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, ...
  • Fleeman N, Houten R, Chaplin M, Beale S, Boland A, ...
  • Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, ...
  • Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, ...
  • Lin CY, Chang JS, Huang SM, Hung CJ, Hung CL, ...
  • Nervo A, Ragni A, Piovesan A, Marica V, Migliore E, ...
  • Razavi Ratki SK, Fallahi B, Namiranian N, Emami-Ardekani A, Saghari ...
  • نمایش کامل مراجع